- Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry2021 | First Faculty of Medicine
- A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry2023 | First Faculty of Medicine
- Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry2022 | First Faculty of Medicine
- Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry2023 | First Faculty of Medicine
- Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study2020 | First Faculty of Medicine
- Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom2024 | First Faculty of Medicine
- Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression2021 | First Faculty of Medicine
- The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis2016 | First Faculty of Medicine
- Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod2018 | First Faculty of Medicine
- Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study2019 | First Faculty of Medicine
- Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis2015 | First Faculty of Medicine
- Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis2018 | First Faculty of Medicine
- Multiple Sclerosis Relapses Following Cessation of Fingolimod2022 | First Faculty of Medicine
- Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity2023 | First Faculty of Medicine
- Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis2016 | First Faculty of Medicine
- Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis2021 | First Faculty of Medicine
- Comparative effectiveness in multiple sclerosis: A methodological comparison2023 | First Faculty of Medicine
- Comparative efficacy of first-line natalizumab vs IFN-Beta or glatiramer acetate in relapsing MS2016 | First Faculty of Medicine
- Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis2021 | First Faculty of Medicine
- Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis2022 | First Faculty of Medicine
- Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis2023 | First Faculty of Medicine
- Confirmed disability progression as a marker of permanent disability in multiple sclerosis2022 | First Faculty of Medicine
- Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry2022 | First Faculty of Medicine
- Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study2022 | First Faculty of Medicine
- Predictors of treatment switching in the Big Multiple Sclerosis Data Network2023 | First Faculty of Medicine
- Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation2023 | First Faculty of Medicine
- Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis2023 | First Faculty of Medicine, Third Faculty of Medicine
- The risk of secondary progressive multiple sclerosis is geographically determined but modifiable2023 | First Faculty of Medicine
- Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis2020 | First Faculty of Medicine